References
- Guha Mazumder D N, Krishna De B, Santra A, Ghosh N, Das S, Lahiri S, Das T. Randomized placebo‐controlled trial of 2,3 dimercapto‐1‐propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic‐contaminated water. J Toxicol Clin Toxicol 2001; 39(7)665–674, [PUBMED], [INFOTRIEVE], [CSA]
- Rahman M M, Chowdhury U K, Mukherjee S C, Mondal B K, Paul K, Lodh D, Biswas B K, Chanda C R, Basu G K, Saha K C, Roy S, Das R, Palit S K, Quamruzzaman Q, Chakraborti D. Chronic arsenic toxicity in Blangadesh and West Bengal, India—a review and commentary. J Toxicol Clin Toxicol 2001; 39(7)683–700, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Michaux I, Haufroid V, Dive A, Buchet J P, Bulpa P, Mahieu P, Installé E. Repetitive endoscopy and continuous alkaline gastric irrigation in a case of arsenic poisoning. J Toxicol Clin Toxicol 2000; 38(5)471–476, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Flora S J, Dube S N, Arora U, Kannan G M, Shukla M K, Malhotra P R. Therapeutic potential of meso 2,3‐dimercaptosuccinic acid or 2.3‐dimercaptopropane‐1‐sulfonate in chronic arsenic intoxication in rats. Biometals 1995; 8(2)111–116, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Muckter H, Lieble B, Reichle F X, Hunder G, Walther U, Fichtl B. Are we ready to replace dimercaprol (BAL) as an arsenic antidote?. Hum Exp Toxicol 1997; 16(8)460–466, [PUBMED], [INFOTRIEVE], [CSA]
- Wax P M, Thornton C A. Recovery from severe arsenic‐induced peripheral neuropathy with 2.3‐dimercapto‐1‐propanesulphoic acid. J Toxicol Clin Toxicol 2000; 38(7)777–780, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Aposhian H V, Maiorino R M, Gonzalez‐Ramirez D, Zuniga‐Charles M, Xu Z, Hurlbut K M, Junco‐Munoz P, Dart R C, Aposhian M M. Mobilisation of heavy metals by newer, therapeutically useful chelating agents. Toxicol 1995; 97(1–3)23–38, [CSA], [CROSSREF]
- Thomas D J, Styblo M, Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 2001; 176: 127–144, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Aposhian H V, Zheng B, Aposhian M M, Le X C, Cebrian M E, Cullen W, Zakharyan R A, Ma M, Dart R C, Cheng Z, Andrewes P, Yip L, O'Malley G F, Maiorino R M, Van Voorhies W, Healy S M, Titcomb A. DMPS‐arsenic challenge test. II. Modulation of arsenic species, including monomethylarsonous acid (MMA(III)), excreted in human urine. Toxicol Appl Pharmacol 2000; 165(1)74–83, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vahter M, Concha G. Role of metabolism in arsenic toxicity. Pharmacol Toxicol 2001; 89: 1–5, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zakharyan R, Aposhian H. Arsenite methylation by methylvitamin B12 and glutathione does not require an enzyme. Toxicol Appl Pharmacol 1999; 154: 287–291, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Aposhian H V, Arroyo A, Cebrian M E, Del Razo L M, Hurlbut K M, Dart R C, Gonzalez‐Ramirez D, Kreppel H, Speisky H, Smith A, Gonsebatt M E, Ostrosky‐Wegman P, Aposhian M M. DMPS‐arsenic challenge test I: increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. JPET 1997; 282: 192–200, [CSA]
- Benramdane L, Accominotti M, Fanton L, Malicier D, Vallon J J. Arsenic speciation in human organs following fatal arsenic trioxide poisoning—a case report. Clin Chem 1999; 45(2)301–306, [PUBMED], [INFOTRIEVE], [CSA]
- Wuyi W. Selenium supplements can prevent arsenic toxicity. Curr Sci 2001; 81: 1215–1218
- Aposhian H V. Mobilisation of mercury and arsenic in humans by sodium 2.3‐dimerdapto‐1‐propane sulfonate (DMPS). Environ Health Perspect 1998; 106(suppl 4)1017–1025, [PUBMED], [INFOTRIEVE], [CSA]